James Miller
Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 44 | 2020 | 2526 | 2.570 |
Why?
| | Smoking | 20 | 2019 | 1627 | 1.200 |
Why?
| | Bronchi | 13 | 2018 | 260 | 1.190 |
Why?
| | Carcinoma in Situ | 5 | 2019 | 49 | 1.090 |
Why?
| | Carcinogens | 4 | 2012 | 125 | 0.740 |
Why?
| | Carcinoma, Squamous Cell | 10 | 2018 | 683 | 0.740 |
Why?
| | Chemoprevention | 3 | 2019 | 92 | 0.710 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 86 | 0.710 |
Why?
| | Lung | 16 | 2020 | 4060 | 0.590 |
Why?
| | Carcinoma, Small Cell | 7 | 2008 | 172 | 0.490 |
Why?
| | Bronchoscopy | 9 | 2019 | 223 | 0.480 |
Why?
| | Urethane | 3 | 2012 | 43 | 0.470 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2019 | 383 | 0.460 |
Why?
| | Sputum | 8 | 2019 | 311 | 0.450 |
Why?
| | Pulmonary Alveoli | 4 | 2012 | 405 | 0.450 |
Why?
| | Iloprost | 2 | 2012 | 45 | 0.450 |
Why?
| | Hyperplasia | 7 | 2011 | 175 | 0.450 |
Why?
| | Precancerous Conditions | 7 | 2020 | 169 | 0.430 |
Why?
| | Neprilysin | 3 | 1998 | 47 | 0.410 |
Why?
| | Quinazolines | 2 | 2012 | 251 | 0.390 |
Why?
| | Piperidines | 2 | 2012 | 206 | 0.380 |
Why?
| | Biomarkers, Tumor | 7 | 2015 | 1276 | 0.380 |
Why?
| | Biopsy | 11 | 2019 | 1129 | 0.380 |
Why?
| | Antineoplastic Agents | 4 | 2013 | 2129 | 0.370 |
Why?
| | DNA Copy Number Variations | 1 | 2011 | 182 | 0.340 |
Why?
| | Bombesin | 5 | 1998 | 11 | 0.340 |
Why?
| | Genetic Markers | 1 | 2011 | 344 | 0.340 |
Why?
| | Amidohydrolases | 3 | 1998 | 31 | 0.330 |
Why?
| | Neurosecretory Systems | 4 | 2004 | 32 | 0.310 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2013 | 1081 | 0.310 |
Why?
| | Ki-67 Antigen | 3 | 2015 | 112 | 0.310 |
Why?
| | Isotretinoin | 1 | 2009 | 26 | 0.310 |
Why?
| | Tocopherols | 1 | 2009 | 26 | 0.310 |
Why?
| | Vasodilator Agents | 1 | 2011 | 331 | 0.310 |
Why?
| | ErbB Receptors | 1 | 2012 | 614 | 0.300 |
Why?
| | Membrane Proteins | 2 | 2008 | 1164 | 0.280 |
Why?
| | Neovascularization, Pathologic | 6 | 2015 | 301 | 0.280 |
Why?
| | Mass Screening | 3 | 2008 | 1287 | 0.280 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2018 | 1040 | 0.270 |
Why?
| | Respiratory Mucosa | 2 | 2008 | 321 | 0.250 |
Why?
| | Adenocarcinoma | 6 | 2012 | 940 | 0.240 |
Why?
| | Hypoxia | 1 | 2012 | 1112 | 0.230 |
Why?
| | Chromosomes, Human, Pair 3 | 4 | 2000 | 50 | 0.220 |
Why?
| | Carcinoma, Bronchogenic | 2 | 2002 | 20 | 0.210 |
Why?
| | Chromosome Aberrations | 4 | 2013 | 156 | 0.210 |
Why?
| | Middle Aged | 28 | 2019 | 33479 | 0.200 |
Why?
| | Tomography, Spiral Computed | 1 | 2002 | 32 | 0.200 |
Why?
| | Aged | 25 | 2019 | 23961 | 0.200 |
Why?
| | Humans | 53 | 2020 | 137585 | 0.180 |
Why?
| | Sensitivity and Specificity | 10 | 2010 | 1946 | 0.180 |
Why?
| | Smokers | 2 | 2019 | 145 | 0.180 |
Why?
| | Female | 33 | 2019 | 73304 | 0.180 |
Why?
| | Placebos | 2 | 2019 | 199 | 0.180 |
Why?
| | Lung Diseases | 5 | 2015 | 767 | 0.180 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2012 | 96 | 0.180 |
Why?
| | Double-Blind Method | 2 | 2019 | 1993 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2691 | 0.160 |
Why?
| | Male | 30 | 2019 | 67762 | 0.160 |
Why?
| | Neuropeptides | 4 | 1998 | 73 | 0.160 |
Why?
| | Tumor Cells, Cultured | 6 | 1998 | 955 | 0.160 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 110 | 0.160 |
Why?
| | Remission Induction | 1 | 2019 | 288 | 0.150 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2010 | 317 | 0.140 |
Why?
| | Peptides | 3 | 1996 | 985 | 0.140 |
Why?
| | Blotting, Western | 4 | 2012 | 1226 | 0.140 |
Why?
| | Genes, p53 | 1 | 1997 | 72 | 0.140 |
Why?
| | Lung Diseases, Obstructive | 1 | 1997 | 50 | 0.140 |
Why?
| | Antibodies, Monoclonal | 3 | 2010 | 1430 | 0.130 |
Why?
| | Immunohistochemistry | 8 | 2015 | 1738 | 0.130 |
Why?
| | Point Mutation | 1 | 1997 | 235 | 0.130 |
Why?
| | Radiation Injuries, Experimental | 1 | 1996 | 22 | 0.120 |
Why?
| | Proteomics | 2 | 2015 | 1111 | 0.120 |
Why?
| | Bradykinin | 1 | 1996 | 46 | 0.120 |
Why?
| | Endopeptidases | 1 | 1996 | 90 | 0.120 |
Why?
| | Chromosomal Instability | 2 | 2013 | 19 | 0.120 |
Why?
| | Hyperoxia | 1 | 1996 | 90 | 0.120 |
Why?
| | Smoking Cessation | 1 | 2019 | 442 | 0.120 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2015 | 23 | 0.120 |
Why?
| | Mice | 10 | 2012 | 17787 | 0.120 |
Why?
| | Animals | 13 | 2013 | 36940 | 0.110 |
Why?
| | Gene Expression | 3 | 1998 | 1502 | 0.110 |
Why?
| | Methylcholanthrene | 2 | 2012 | 22 | 0.110 |
Why?
| | Antigens | 1 | 1996 | 357 | 0.110 |
Why?
| | Butylated Hydroxytoluene | 2 | 2012 | 38 | 0.110 |
Why?
| | Mice, Transgenic | 5 | 2009 | 2167 | 0.110 |
Why?
| | Risk Factors | 5 | 2019 | 10388 | 0.110 |
Why?
| | Microarray Analysis | 1 | 2013 | 117 | 0.110 |
Why?
| | Stem Cells | 1 | 2018 | 594 | 0.100 |
Why?
| | Algorithms | 3 | 2020 | 1704 | 0.100 |
Why?
| | Aged, 80 and over | 8 | 2015 | 7635 | 0.100 |
Why?
| | Mutation | 4 | 2000 | 3958 | 0.100 |
Why?
| | Epithelium | 4 | 2018 | 313 | 0.100 |
Why?
| | Intramolecular Oxidoreductases | 2 | 2004 | 68 | 0.100 |
Why?
| | Carcinoma, Large Cell | 1 | 2012 | 16 | 0.100 |
Why?
| | Risk | 5 | 2012 | 912 | 0.100 |
Why?
| | Biological Products | 1 | 1996 | 216 | 0.100 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2004 | 155 | 0.100 |
Why?
| | Epithelial Cells | 3 | 2007 | 1096 | 0.100 |
Why?
| | Receptors, Bombesin | 1 | 2012 | 2 | 0.100 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2002 | 652 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 219 | 0.090 |
Why?
| | Volatile Organic Compounds | 1 | 2012 | 61 | 0.090 |
Why?
| | Cell Division | 4 | 2000 | 794 | 0.090 |
Why?
| | Case-Control Studies | 8 | 2012 | 3556 | 0.090 |
Why?
| | Sleep Apnea Syndromes | 1 | 2012 | 88 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 2057 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2012 | 139 | 0.090 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 2011 | 55 | 0.090 |
Why?
| | Eosinophilic Granuloma | 1 | 1990 | 3 | 0.090 |
Why?
| | Veterans | 1 | 2002 | 1476 | 0.090 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2012 | 209 | 0.080 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 243 | 0.080 |
Why?
| | Antioxidants | 2 | 2012 | 584 | 0.080 |
Why?
| | Plants, Toxic | 1 | 1989 | 24 | 0.080 |
Why?
| | Cell Line | 5 | 2013 | 2847 | 0.080 |
Why?
| | Proteins | 1 | 1996 | 1009 | 0.080 |
Why?
| | Somatomedins | 1 | 2009 | 27 | 0.080 |
Why?
| | Calcium | 1 | 1996 | 1199 | 0.080 |
Why?
| | Genome-Wide Association Study | 2 | 2013 | 1431 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2009 | 2031 | 0.080 |
Why?
| | Disease Progression | 5 | 2018 | 2757 | 0.080 |
Why?
| | Cell Proliferation | 2 | 2018 | 2475 | 0.080 |
Why?
| | Bronchial Neoplasms | 1 | 2009 | 15 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2011 | 455 | 0.080 |
Why?
| | Chromosome Deletion | 1 | 1989 | 115 | 0.080 |
Why?
| | Adult | 16 | 2018 | 37929 | 0.070 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2009 | 49 | 0.070 |
Why?
| | Airway Obstruction | 3 | 2009 | 162 | 0.070 |
Why?
| | Respiratory System | 1 | 1989 | 157 | 0.070 |
Why?
| | GPI-Linked Proteins | 1 | 2008 | 73 | 0.070 |
Why?
| | Neoplasm Invasiveness | 4 | 2015 | 510 | 0.070 |
Why?
| | Fluorescence | 3 | 2009 | 160 | 0.070 |
Why?
| | Alkaline Phosphatase | 1 | 2008 | 148 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 660 | 0.070 |
Why?
| | Spectral Karyotyping | 1 | 2007 | 5 | 0.070 |
Why?
| | Isoenzymes | 1 | 2008 | 304 | 0.070 |
Why?
| | Molecular Targeted Therapy | 1 | 2010 | 411 | 0.070 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2009 | 327 | 0.070 |
Why?
| | Inflammation | 1 | 2018 | 2837 | 0.070 |
Why?
| | Molecular Sequence Data | 5 | 1998 | 2900 | 0.070 |
Why?
| | Pulmonary Surfactants | 2 | 1999 | 106 | 0.070 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2008 | 267 | 0.070 |
Why?
| | Fibroblasts | 3 | 1998 | 996 | 0.070 |
Why?
| | Exons | 2 | 1998 | 355 | 0.060 |
Why?
| | MicroRNAs | 1 | 2012 | 692 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2015 | 5131 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2189 | 0.060 |
Why?
| | Early Detection of Cancer | 1 | 2010 | 447 | 0.060 |
Why?
| | ROC Curve | 3 | 2015 | 554 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2005 | 852 | 0.060 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 430 | 0.060 |
Why?
| | Recombinant Proteins | 3 | 1998 | 1353 | 0.060 |
Why?
| | Biomarkers | 3 | 2010 | 4149 | 0.060 |
Why?
| | Polymerase Chain Reaction | 3 | 1998 | 1062 | 0.060 |
Why?
| | RNA, Messenger | 3 | 1998 | 2833 | 0.060 |
Why?
| | Growth Hormone-Releasing Hormone | 1 | 2004 | 24 | 0.060 |
Why?
| | Acromegaly | 1 | 2004 | 14 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 916 | 0.050 |
Why?
| | Cytokines | 1 | 2012 | 2085 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 143 | 0.050 |
Why?
| | Rats | 4 | 2004 | 5647 | 0.050 |
Why?
| | Smoke | 1 | 2004 | 141 | 0.050 |
Why?
| | Base Sequence | 3 | 1998 | 2181 | 0.050 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2002 | 22 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 1079 | 0.050 |
Why?
| | Metaplasia | 2 | 2018 | 60 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 545 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 5472 | 0.050 |
Why?
| | Sex Factors | 1 | 2007 | 2071 | 0.050 |
Why?
| | Hospitals, Veterans | 1 | 2002 | 252 | 0.040 |
Why?
| | Pulmonary Fibrosis | 2 | 1998 | 402 | 0.040 |
Why?
| | Radiation Dosage | 1 | 2002 | 179 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3284 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 1989 | 2607 | 0.040 |
Why?
| | Amino Acid Sequence | 3 | 1994 | 2139 | 0.040 |
Why?
| | Cohort Studies | 4 | 2015 | 5742 | 0.040 |
Why?
| | Gastrin-Releasing Peptide | 2 | 1996 | 7 | 0.040 |
Why?
| | Autocrine Communication | 1 | 1998 | 41 | 0.040 |
Why?
| | Desmoglein 3 | 1 | 2018 | 15 | 0.040 |
Why?
| | gamma Catenin | 1 | 2018 | 13 | 0.040 |
Why?
| | Light | 1 | 2001 | 381 | 0.040 |
Why?
| | Loss of Heterozygosity | 2 | 2013 | 51 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2002 | 956 | 0.040 |
Why?
| | DNA Primers | 2 | 1998 | 515 | 0.040 |
Why?
| | Signal Transduction | 3 | 1998 | 5079 | 0.040 |
Why?
| | Up-Regulation | 2 | 2005 | 843 | 0.040 |
Why?
| | Bronchial Diseases | 1 | 2018 | 37 | 0.040 |
Why?
| | Paracrine Communication | 1 | 1998 | 65 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 1998 | 257 | 0.040 |
Why?
| | Time | 1 | 2018 | 83 | 0.040 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 1998 | 39 | 0.040 |
Why?
| | Telangiectasia, Hereditary Hemorrhagic | 1 | 1998 | 13 | 0.040 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1997 | 26 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 98 | 0.040 |
Why?
| | Genes, Tumor Suppressor | 1 | 1998 | 86 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1774 | 0.040 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 1998 | 97 | 0.040 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 68 | 0.030 |
Why?
| | Likelihood Functions | 1 | 1998 | 144 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1998 | 272 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 1998 | 283 | 0.030 |
Why?
| | Codon | 1 | 1997 | 89 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2012 | 1389 | 0.030 |
Why?
| | Introns | 1 | 1998 | 258 | 0.030 |
Why?
| | United States | 2 | 2011 | 14841 | 0.030 |
Why?
| | Mice, Nude | 1 | 1998 | 698 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1999 | 500 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2011 | 10811 | 0.030 |
Why?
| | Immunoassay | 2 | 1998 | 115 | 0.030 |
Why?
| | Incidence | 3 | 2010 | 2804 | 0.030 |
Why?
| | Enzyme Activation | 1 | 1998 | 810 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 1996 | 82 | 0.030 |
Why?
| | Glycopeptides | 1 | 1996 | 43 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 752 | 0.030 |
Why?
| | Mesothelioma | 1 | 1996 | 44 | 0.030 |
Why?
| | Antigens, CD | 2 | 1998 | 521 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 812 | 0.030 |
Why?
| | Machine Learning | 1 | 2020 | 493 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 648 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1357 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 617 | 0.030 |
Why?
| | Receptors, Peptide | 1 | 1994 | 17 | 0.030 |
Why?
| | Myelin Sheath | 1 | 1996 | 167 | 0.030 |
Why?
| | Rh-Hr Blood-Group System | 1 | 1994 | 12 | 0.030 |
Why?
| | Erythrocyte Membrane | 1 | 1994 | 55 | 0.030 |
Why?
| | Blotting, Southern | 1 | 1993 | 73 | 0.030 |
Why?
| | Blotting, Northern | 1 | 1993 | 201 | 0.030 |
Why?
| | Prospective Studies | 3 | 2012 | 7604 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 1996 | 658 | 0.030 |
Why?
| | DNA, Neoplasm | 1 | 1993 | 164 | 0.020 |
Why?
| | Solid Phase Microextraction | 1 | 2012 | 9 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2007 | 4193 | 0.020 |
Why?
| | Endoscopy | 1 | 2015 | 318 | 0.020 |
Why?
| | Dinoprostone | 2 | 2004 | 191 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 1993 | 390 | 0.020 |
Why?
| | Cloning, Molecular | 1 | 1993 | 534 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2012 | 132 | 0.020 |
Why?
| | Breath Tests | 1 | 2012 | 87 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 1996 | 840 | 0.020 |
Why?
| | Colorado | 1 | 2002 | 4565 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1396 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 1998 | 786 | 0.020 |
Why?
| | Iceland | 1 | 2011 | 11 | 0.020 |
Why?
| | Tumor Suppressor p53-Binding Protein 1 | 1 | 2011 | 13 | 0.020 |
Why?
| | Spain | 1 | 2011 | 41 | 0.020 |
Why?
| | Netherlands | 1 | 2011 | 88 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 1992 | 184 | 0.020 |
Why?
| | Cattle | 1 | 1993 | 984 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 816 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 1996 | 2486 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2011 | 186 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2828 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2009 | 65 | 0.020 |
Why?
| | Carrier Proteins | 1 | 1994 | 771 | 0.020 |
Why?
| | Flow Cytometry | 1 | 1993 | 1178 | 0.020 |
Why?
| | Prognosis | 2 | 2012 | 4030 | 0.020 |
Why?
| | Area Under Curve | 1 | 2010 | 314 | 0.020 |
Why?
| | International Agencies | 1 | 2009 | 35 | 0.020 |
Why?
| | Cystic Fibrosis | 1 | 1998 | 1114 | 0.020 |
Why?
| | Erythrocytes | 1 | 1994 | 700 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1989 | 597 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 739 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1710 | 0.020 |
Why?
| | Genome, Human | 1 | 2009 | 425 | 0.020 |
Why?
| | Models, Statistical | 1 | 2010 | 669 | 0.020 |
Why?
| | Amino Acids | 1 | 1989 | 497 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1916 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 1996 | 4295 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 108 | 0.010 |
Why?
| | Genomics | 1 | 2009 | 795 | 0.010 |
Why?
| | Epoprostenol | 1 | 2004 | 136 | 0.010 |
Why?
| | Bronchiolitis | 1 | 2004 | 80 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 976 | 0.010 |
Why?
| | Autoantibodies | 1 | 2010 | 1496 | 0.010 |
Why?
| | Fruit | 1 | 2003 | 140 | 0.010 |
Why?
| | Vegetables | 1 | 2003 | 157 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 767 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 600 | 0.010 |
Why?
| | Pituitary Neoplasms | 1 | 2004 | 190 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2011 | 2426 | 0.010 |
Why?
| | Adenoma | 1 | 2004 | 230 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 1024 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2001 | 282 | 0.010 |
Why?
| | Weight Gain | 1 | 2004 | 519 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 52 | 0.010 |
Why?
| | Carcinoma | 1 | 2001 | 240 | 0.010 |
Why?
| | Bronchoscopes | 1 | 1998 | 4 | 0.010 |
Why?
| | RNA | 1 | 2005 | 921 | 0.010 |
Why?
| | Endoglin | 1 | 1998 | 19 | 0.010 |
Why?
| | Random Allocation | 1 | 1998 | 353 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1998 | 297 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2015 | 15657 | 0.010 |
Why?
| | Reference Values | 1 | 1998 | 816 | 0.010 |
Why?
| | Comorbidity | 1 | 2001 | 1622 | 0.010 |
Why?
| | Linear Models | 1 | 1998 | 849 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2003 | 2844 | 0.010 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2000 | 528 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1998 | 1316 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 1998 | 385 | 0.010 |
Why?
| | Diet | 1 | 2003 | 1278 | 0.010 |
Why?
| | Alleles | 1 | 1998 | 891 | 0.010 |
Why?
| | Young Adult | 1 | 2011 | 13209 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 3457 | 0.010 |
Why?
| | Chromatography, Affinity | 1 | 1994 | 88 | 0.010 |
Why?
| | Infant, Premature | 1 | 1998 | 574 | 0.010 |
Why?
| | CD47 Antigen | 1 | 1994 | 38 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2000 | 927 | 0.010 |
Why?
| | Genes | 1 | 1994 | 230 | 0.010 |
Why?
| | Moths | 1 | 1994 | 45 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 345 | 0.010 |
Why?
| | Cytoplasm | 1 | 1994 | 274 | 0.010 |
Why?
| | Carcinoid Tumor | 1 | 1992 | 26 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1994 | 523 | 0.010 |
Why?
| | Lymphocytes | 1 | 1994 | 397 | 0.010 |
Why?
| | Transfection | 1 | 1994 | 945 | 0.010 |
Why?
| | Adolescent | 1 | 2011 | 21513 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1994 | 1272 | 0.010 |
Why?
| | Binding Sites | 1 | 1994 | 1303 | 0.010 |
Why?
| | Dyspnea | 1 | 1992 | 254 | 0.010 |
Why?
| | Fibrosis | 1 | 1992 | 552 | 0.010 |
Why?
| | Phenotype | 1 | 1998 | 3196 | 0.000 |
Why?
| | Aging | 1 | 1998 | 1864 | 0.000 |
Why?
| | Infant, Newborn | 1 | 1998 | 6079 | 0.000 |
Why?
| | Infant | 1 | 1998 | 9465 | 0.000 |
Why?
| | Child, Preschool | 1 | 1998 | 11074 | 0.000 |
Why?
| | Child | 1 | 1998 | 21935 | 0.000 |
Why?
|
|
Miller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|